Navigation Links
$89 Million Proposed Class Action Settlement Provides Consumers and Insurers With Money Back for Celebrex and Bextra Purchases and Reimbursements
Date:4/29/2009

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- A federal court in San Francisco has granted preliminary approval to a proposed settlement with Pfizer Inc. ("Pfizer") about the marketing of the prescription drugs Bextra and Celebrex. The settlement in the case called In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-CV-01669, MDL No. 1699, pending in the United States District Court for the Northern District of California, will provide a Settlement Fund of $89 million to benefit a class of consumers and insurance companies or other entities (also called Third-Party Payors) that paid for either medicine before July 29, 2005.

The lawsuit, which does not concern safety risk of either drug, claims that Pfizer falsely advertised Bextra and Celebrex as having greater benefits than less expensive pain medications, causing consumers and other entities to pay a greater price for Bextra and Celebrex than they would otherwise have paid for less expensive alternatives or no medications at all. The lawsuit also claims that the advertising was not consistent with the drugs' Food and Drug Administration approved labeling. Pfizer denies any wrongdoing and denies all of the claims in the lawsuit but is settling this lawsuit to avoid the cost and expense of further litigation.

Consumers who paid for Bextra and/or Celebrex on or before July 29, 2005 are included in the Proposed Settlement. Third-Party Payors that paid or reimbursed for all or a percentage of the cost of Bextra and/or Celebrex on or before July 29, 2005 can also make a recovery under the Proposed Settlement. Third-Party Payors include insurance companies, union health and welfare plans, and self-insured employers.

Consumers and Third-Party Payors that wish to remain in the Settlement and file a claim will be bound by the Court's orders and will give up the right to sue the defendants on their own. Claim forms must be postmarked by October 23, 2009.

The Court will hold a Final Approval Hearing on September 25, 2009 at 10 a.m. to consider whether the Proposed Settlement is fair, reasonable, and adequate and the motion for attorneys' fees and expenses. For more information, including a claim form, Class Members may call toll-free 1-800-547-9360, visit www.BextraCelebrexSettlement.com, or write: Bextra and Celebrex Claims Administrator, c/o Rust Consulting, Inc., P.O. Box 24675, West Palm Beach, FL 33416.


'/>"/>
SOURCE Bextra and Celebrex Claims Administrator
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Registered Organ Donors Near Five Million, Save 300 Lives Since 2006
2. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
3. FSU researcher wins $2.2 million grant to study childhood obesity
4. UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa
5. Treatment Options Increase For Millions with Fibromyalgia
6. Attorney General Eric Holder Honors Florida Doctor and Announces $4.7 Million in Recovery Act Funds for State
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Working Towards Counting Malaria Out Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance
9. Millions of Youth Around the World Volunteer to Improve Communities
10. Proposed $350 Million Class Action Settlement Regarding Drug Pricing Provides Consumers and Third-Party Payors With Money Back
11. The Female Health Company / HLL Lifecare Limited Receive National AIDS Control Organization of India Order for 1.5 Million FC2 Female Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... that Lake City Bank has selected IFN as a fiber transport provider. IFN ... in increased efficiencies and reduced costs. , “IFN provides fiber transport ...
(Date:5/25/2016)... ... 2016 , ... CloudLIMS, joins an elite number of companies that have earned ... of 2016 by CIOReview. , In a deliberate session with the honorary industrial experts, ... has been concluded with. The positioning is based on evaluation of CloudLIMS’ specialties in ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... and products in the developing world, is pleased to release their 2015 global ... 5 million unwanted pregnancies, almost 14,000 maternal deaths and 3.8 million unsafe abortions ...
(Date:5/25/2016)... ... 2016 , ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, ... new wellness suites . The two 1,350 sq. ft. suites which debuted in ... and insuite amenities, from a custom soap selection and in-suite exercise kit to a ...
(Date:5/25/2016)... ... ... For more than fifty years, we've suffered whiplash as each new scientific study seemed to ... latest nutritional advice – advice that was supposed to keep us healthy and slim. And ... adults are considered to be overweight and more than 1 in 3 adults are considered ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
Breaking Medicine Technology: